NO20060001L - Nye P2X7-reseptorantagonister og deres anvendelse - Google Patents

Nye P2X7-reseptorantagonister og deres anvendelse

Info

Publication number
NO20060001L
NO20060001L NO20060001A NO20060001A NO20060001L NO 20060001 L NO20060001 L NO 20060001L NO 20060001 A NO20060001 A NO 20060001A NO 20060001 A NO20060001 A NO 20060001A NO 20060001 L NO20060001 L NO 20060001L
Authority
NO
Norway
Prior art keywords
novel
receptor antagonists
therapy
formula
preparation
Prior art date
Application number
NO20060001A
Other languages
English (en)
Norwegian (no)
Inventor
Paul Andrew Willis
Richard Evans
Rhonan Ford
Christine Eyssade
Barrie Martin
Toby Thompson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38812906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060001(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060001L publication Critical patent/NO20060001L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20060001A 2003-06-02 2006-01-02 Nye P2X7-reseptorantagonister og deres anvendelse NO20060001L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0312609.1A GB0312609D0 (en) 2003-06-02 2003-06-02 Novel compounds
SE0301700A SE0301700D0 (sv) 2003-06-02 2003-06-10 Novel compounds
PCT/SE2004/000836 WO2004106305A1 (en) 2003-06-02 2004-06-01 New p2x7 receptor antagonists and their use

Publications (1)

Publication Number Publication Date
NO20060001L true NO20060001L (no) 2006-03-02

Family

ID=38812906

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060001A NO20060001L (no) 2003-06-02 2006-01-02 Nye P2X7-reseptorantagonister og deres anvendelse

Country Status (26)

Country Link
US (2) US7408065B2 (de)
EP (1) EP1633717B1 (de)
JP (1) JP4682128B2 (de)
KR (1) KR101244971B1 (de)
CN (1) CN1832925B (de)
AR (1) AR045691A1 (de)
AT (1) ATE446953T1 (de)
AU (1) AU2004242626B2 (de)
BR (1) BRPI0410933A (de)
CA (1) CA2526884C (de)
CO (1) CO5700720A2 (de)
DE (1) DE602004023840D1 (de)
ES (1) ES2333721T3 (de)
GB (1) GB0312609D0 (de)
HK (1) HK1085736A1 (de)
IS (1) IS8190A (de)
MX (1) MXPA05012883A (de)
NO (1) NO20060001L (de)
RU (1) RU2347778C2 (de)
SA (1) SA04250155B1 (de)
SE (1) SE0301700D0 (de)
TW (1) TW200508214A (de)
UA (1) UA83659C2 (de)
UY (1) UY28342A1 (de)
WO (1) WO2004106305A1 (de)
ZA (1) ZA200509706B (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
JP2008513426A (ja) * 2004-09-20 2008-05-01 バイオリポックス エービー 炎症の治療に有用なピラゾール化合物
BRPI0606437A (pt) * 2005-01-06 2008-03-11 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, e, método de tratamento de um distúrbio de agregação de plaqueta
US7297700B2 (en) * 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
KR20080039405A (ko) * 2005-07-13 2008-05-07 아스트라제네카 아베 신규한 피리딘 유사체
KR20080036125A (ko) * 2005-08-01 2008-04-24 페노믹스 코포레이션 헤테로시클릭 보론산 및 그의 유도체의 제조 방법
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
TW200800911A (en) * 2005-10-20 2008-01-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
EA200801108A1 (ru) * 2005-10-31 2008-10-30 Биолипокс Аб Триазолы, пригодные для лечения воспалений
TW200732320A (en) * 2005-10-31 2007-09-01 Biolipox Ab Pyrazoles useful in the treatment of inflammation
WO2007052000A1 (en) * 2005-11-01 2007-05-10 Biolipox Ab Pyrazoles useful in the treatment of inflammation
US8007849B2 (en) 2005-12-14 2011-08-30 International Flavors & Fragrances Inc. Unsaturated cyclic and acyclic carbamates exhibiting taste and flavor enhancement effect in flavor compositions
DK1937643T3 (en) * 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
JP2009541205A (ja) * 2006-03-16 2009-11-26 レノビス， インコーポレイテッド Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用
EP2001474B1 (de) * 2006-03-16 2016-03-09 Second Genome, Inc. Bicycloheteroaryl-verbindungen als px27-modulatoren und ihre verwendungen
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
WO2008013494A1 (en) * 2006-07-27 2008-01-31 Astrazeneca Ab Quinoline derivatives as p2x7 receptor antagonist and their use in the treatment of rheumatoid arthritis, osteoarthritis, copd and ibd
ATE478050T1 (de) * 2006-09-28 2010-09-15 Hoffmann La Roche Chinolinderivate mit 5-ht-bindenden eigenschaften
EA018036B1 (ru) 2006-11-27 2013-05-30 Х. Лундбекк А/С Гетероариламидные производные
MX2009005509A (es) * 2006-12-07 2009-06-03 Hoffmann La Roche 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
ES2388454T3 (es) * 2007-03-22 2012-10-15 Astrazeneca Ab Derivados de quinolina para el tratamiento de enfermedades inflamatorias
CA2682925A1 (en) * 2007-04-10 2008-10-16 David C. Ihle Heteroaryl amide analogues
PE20091036A1 (es) * 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
WO2009108551A2 (en) * 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
CA2715842A1 (en) 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-aminoquinoline derivatives
PL2105164T3 (pl) 2008-03-25 2011-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści P2X7R i ich zastosowanie
AU2009239471B2 (en) * 2008-04-22 2013-01-24 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
PL2243772T3 (pl) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści p2x7r i ich zastosowanie
CA2761639C (en) * 2009-05-29 2016-06-07 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
WO2011141194A1 (en) 2010-05-14 2011-11-17 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
AR087274A1 (es) 2011-07-22 2014-03-12 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7
WO2013108227A1 (en) 2012-01-20 2013-07-25 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
AU2013356850B2 (en) 2012-12-12 2018-02-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonists
CN104854087B (zh) 2012-12-18 2017-03-22 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的吲哚羧酰胺衍生物
CN104918946B (zh) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
CN104918617B (zh) 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
JP6294953B2 (ja) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節物質
US10053463B2 (en) 2013-03-14 2018-08-21 Janssen Pharmaceutica Nv Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
AU2015269598B2 (en) * 2014-06-05 2019-11-14 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｐ２ｘ７調節因子
CN106084068B (zh) * 2016-06-16 2019-07-16 郑州大学第一附属医院 一组肠菌素-抗生素衍生物及其应用
PT3609868T (pt) * 2017-03-13 2023-12-18 Raqualia Pharma Inc Derivados de tetra-hidroquinolina como antagonistas do recetor p2x7
EP3398941A1 (de) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
MA53721A (fr) 2018-09-28 2021-09-15 Janssen Pharmaceutica Nv Modulateurs de la monoacylglycérol lipase
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
BR112022019077A2 (pt) 2020-03-26 2022-12-27 Janssen Pharmaceutica Nv Moduladores da monoacilglicerol lipase

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US3741491A (en) * 1971-11-29 1973-06-26 Leesona Corp Apparatus for winding yarn
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
EP0501656B1 (de) 1991-02-21 1997-01-22 Sankyo Company Limited Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
ATE246677T1 (de) 1994-05-27 2003-08-15 Smithkline Beecham Farma Chinolinderivate als tachykinin nk3 rezeptor antagonisten
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
PL329922A1 (en) 1996-05-20 1999-04-26 Darwin Discovery Ltd Quinoline carboxamides as inhibitors of the tumour necrosis factor and of phosphodiesterase
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2001524468A (ja) 1997-11-21 2001-12-04 エヌピーエス ファーマシューティカルズ インコーポレーテッド 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
NZ514477A (en) 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
CN1361768A (zh) 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
NZ540351A (en) * 1999-11-26 2006-05-26 Shionogi & Co NPY Y5 antagonists
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
JP4523273B2 (ja) 2001-07-02 2010-08-11 ナームローゼ・フエンノートチヤツプ・オルガノン テトラヒドロキノリン誘導体
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds

Also Published As

Publication number Publication date
EP1633717B1 (de) 2009-10-28
CN1832925B (zh) 2010-05-05
JP2006526617A (ja) 2006-11-24
KR101244971B1 (ko) 2013-03-18
SA04250155B1 (ar) 2008-11-15
AU2004242626A1 (en) 2004-12-09
ATE446953T1 (de) 2009-11-15
RU2005136130A (ru) 2006-06-27
DE602004023840D1 (de) 2009-12-10
CO5700720A2 (es) 2006-11-30
US7408065B2 (en) 2008-08-05
JP4682128B2 (ja) 2011-05-11
MXPA05012883A (es) 2006-02-22
WO2004106305A1 (en) 2004-12-09
TW200508214A (en) 2005-03-01
GB0312609D0 (en) 2003-07-09
AU2004242626B2 (en) 2008-03-13
UY28342A1 (es) 2004-12-31
IS8190A (is) 2005-12-21
KR20060015741A (ko) 2006-02-20
BRPI0410933A (pt) 2006-06-27
ZA200509706B (en) 2006-12-27
US20090143354A1 (en) 2009-06-04
UA83659C2 (ru) 2008-08-11
EP1633717A1 (de) 2006-03-15
US20060293337A1 (en) 2006-12-28
SE0301700D0 (sv) 2003-06-10
HK1085736A1 (en) 2006-09-01
CA2526884C (en) 2012-10-16
RU2347778C2 (ru) 2009-02-27
AR045691A1 (es) 2005-11-09
ES2333721T3 (es) 2010-02-26
CA2526884A1 (en) 2004-12-09
CN1832925A (zh) 2006-09-13

Similar Documents

Publication Publication Date Title
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20066055L (no) Pyridinderivater
NO20090628L (no) Pyridizinon derivativater
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
NO20071593L (no) Pyrimidinderivater
NO20044826L (no) Pyrrolidinderivater
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20081844L (no) Terapeutiske forbindelser
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20054312L (no) HIV-replikasjonsinhiberende pyrimidiner og triaziner
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
BR0016396A (pt) Novos antagonistas do receptor p2x7 para uso no tratamento de doenças inflamatórias, imunes ou cardiovasculares
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20071504L (no) Pyrimidinderivanter.
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
TW200613243A (en) Novel compounds
NO20062900L (no) Nye forbindelser
NO20052683D0 (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1730147T3 (da) Substituerede 1,4,8-triazaspiro[4.5]decan-2-on-forbindelser til behandling af fedme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application